MELBOURNE Australia 21 March 2017: AdAlta Limited (ASX: 1AD), the biotechnology company advancing AD-114, its lead i-body candidate for the treatment of idiopathic pulmonary fibrosis (IPF) and other human fibrotic diseases towards clinical development, is pleased to release the full length videos of each speaker from its R&D briefing meeting on fibrosis for analysts and investors.
Fibrosis accounts for 45% of all diseases globally in the developed world and represents a large unmet medical need.
These following presentations and videos from the symposium included:
- Dr Robert Peach, Non-Executive Director, AdAlta’s Board, Receptos story – From NZ to the US, a Phase III antibody and an $8B acquisition;
- Associate Professor Michael Foley, La Trobe University, AD-114 a novel i-body for the treatment of fibrosis;
- Dr Glen Westall, Alfred Hospital, Pulmonary fibrosis – current state of play in Idiopathic Pulmonary Fibrosis (IPF);
- Dr Muh Geot Wong, Kolling Institute Renal fibrosis and chronic kidney disease;
- Professor Erica Fletcher, University of Melbourne, eye fibrosis, causes, diseases and treatments;
- A closing panel chaired by Stuart Roberts, including Dr Brian Richardson, Dr John Westwick and Dr Robert Peach; and
- Sam Cobb, CEO of AdAlta also provided an update on Company activities.
To find out more about AdAlta, contact Sam Cobb, CEO, Tel: (03) 9479 5159 or email email@example.com.
Notes to editors
AdAlta Limited (ASX:1AD) is an Australian based drug development company headquartered in Melbourne. The Company is focused on using its proprietary technology platform to generate i-bodies, a new class of protein therapeutics, with applications as therapeutic drugs to treat diseases. AdAlta is developing its lead i-body candidate, AD-114, for the treatment of idiopathic pulmonary fibrosis (IPF) and other human fibrotic diseases, for which current therapies are sub-optimal and there is a high-unmet medical need. AD-114 has strong pre-clinical results for IPF, demonstrating both anti-fibrotic and anti-inflammatory activity in human lung tissue and indicating greater efficacy than existing approved IPF drugs. The i-body is a human analogue of the antigen binding domain of the shark antibody, which combines the advantages of monoclonal antibodies (high target specificity and affinity) with the beneficial stability features of small molecules. In addition to stability, the i-body has a long binding loop that is a feature of shark antibodies not present in either human or next generation antibodies. This feature enables the i-body to recognise and bind to a diverse range of different therapeutically-relevant drug targets, including those that are difficult/intractable to access by current antibody therapies. These include clinically important targets such as G-protein coupled receptors (GPCRs) and ion channels.
Chief Executive Officer
Tel: +61 (0) 3 9479 5159
Tel: +61 (0) 408 677 734
Sue Charles/Daniel Gooch
Tel: +44 (0) 20 7866 7905